Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety and immunogenicity of monovalent OPV2 in children aged 1 to 5 years in Lithuania has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• Monovalent OPV2 (monovalent oral polio vaccine serotype 2)

Snippet

Sponsor: Fidec Corporation | Conditions: Poliomyelitis | Phase 4 | Status: COMPLETED | Results posted: 2019-12-16